• 15 Jul 2024
• Admin
• News Article

Chiesi’s Rare Disorder Therapies Approved by SMC for Fabry Disease and Epidermolysis Bullosa

Overview

Chiesi has announced that the Scottish Medicines Consortium (SMC) has approved its two rare disease therapies, Elfabrio (pegunigalsidase alfa) and Filsuvez (birch bark extract gel), to treat Fabry disease and junctional and dystrophic epidermolysis bullosa (EB), respectively.

Elfabrio: Indication

Elfabrio has been indicated for use in adults living with the debilitating genetic disease, while Filsuvez has been approved for use in patients aged six months and older, subject to data collection under the SMC’s ultra-orphan medicines framework expected by September.

Rare Diseases in Scotland

Rare diseases affect around 436,000 people in Scotland and the SMC’s approval aligns with the Scottish government’s action plan for rare diseases by improving access to specialist treatments, one of the four key priorities outlined in the UK Rare Diseases Framework.

Results from Phase 3

• The SMC’s decision on Elfabrio, a novel enzyme replacement therapy, was based on positive results from phase 3 clinical trials involving 142 Fabry disease patients, of whom 112 received Elfabrio 1mg every other week, and comes after the National Institute for Health and Care Excellence recommended the therapy in 2023.
• The studies showed that Elfabrio was well tolerated and was similarly clinically effective and more cost-effective compared to the current treatments being used in the NHS, agalsidase alfa and migalastat.

About Fabry disease

Affecting around one in 40,000 people, Fabry disease is a rare, progressive, X-linked inherited lysosomal storage disorder that causes chronic pain and progressive damage to vital organs, including the heart, kidneys and brain.

Filsuvez Approvals

Previously approved by the European Medicines Agency, Filsuvez is a sterile gel for cutaneous application used for the treatment of partial-thickness wounds associated with dystrophic and junctional EB and is currently the only licenced therapy for this patient population.

Skin Disorder: EB

EB is a heterogenous group of rare inherited skin disorders caused by mutations in the genes that encode skin anchoring proteins of the dermo-epidermal junction and is characterised by fragile skin that is prone to blistering and erosions due to minor trauma or friction anywhere on the body.

From an Expert on Approvals

Commenting on the approvals, David Garzón Lafuente, head of rare diseases, Chiesi UK and Ireland, said: “The positive announcements for [Elfabrio] and [Filsuvez] by the SMC are a result of close collaborative working between patient organisations… to support as many people living with a rare disease as possible.”